Skip to main
ERAS

Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca Inc (ERAS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Erasca is a clinical-stage precision oncology company with a promising pipeline focused on RAS/MAPK driven cancers. The recent data update for ERAS-0015, a pan-RAS molecular glue, has demonstrated encouraging early stage data and management has reported high enrollment rates for their AURORAS-1 Phase 1 dose escalation. With a potential best-in-class therapy and multi-blockbuster opportunities, Erasca is well-positioned for success in the large RAS-mutant market. However, there are risks to consider, such as regulatory and commercial risks. With these factors in mind, the 3rd person analyst has a positive outlook on Erasca's stock with a projected price target of $18.

Bears say

Erasca is a clinical-stage precision oncology company focused on discovering and developing therapies for patients with RAS/MAPK pathway-driven cancers. Despite the company's growing confidence in their lead drug candidate, ERAS-0015, there are significant risks involved that could hinder the drug's success, such as regulatory and financial risks. Topline data for ERAS-0015 and ERAS-4001, as well as updates on strategic focus and enrollment in expansion cohorts, will be important factors to reassess the company's potential market opportunity in multi-billion dollar indications.

Erasca Inc (ERAS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Erasca Inc (ERAS) Forecast

Analysts have given Erasca Inc (ERAS) a Buy based on their latest research and market trends.

According to 9 analysts, Erasca Inc (ERAS) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Erasca Inc (ERAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.